AXTA vs EMN

AXTA's deterministic scorecard shows a Piotroski F-Score of 4/9, indicating stable but not strong financial health, and the absence of an Altman Z-Score prevents a full distress risk assessment. The stock trades below the growth-based intrinsic value of $48.10 but above the conservative Graham Number of $22.25, suggesting mixed valuation signals. Despite solid profitability metrics like a 21.33% ROE and consistent earnings beats, revenue is contracting YoY by 2.40%, and insider activity is bearish with recent selling. Analysts recommend a 'buy' with a $36.71 target, implying moderate upside from current levels around $33.62.

Eastman Chemical Company exhibits significant fundamental deterioration, highlighted by a Piotroski F-Score of 4/9 (Stable but weak) and a severe earnings collapse of -67.5% YoY. While the current price of $72.00 sits near the Graham Number ($69.44), it trades at a massive premium to its growth-based intrinsic value of $28.70. The combination of negative revenue growth, a high dividend payout ratio (81.22%), and a bearish technical trend (0/100) suggests the stock is overvalued relative to its current trajectory.